ATOSSA THERAPEUTICS, INC. ATOS Balance Sheet

Atossa therapeutics, inc. (ATOS)

Balance Sheet / Yearly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Dec'11
Current assets
Cash and cash equivalents
9,351	12,581	15,289	17,058	19,568	10,380	12,935	15,236	4,779	7,217	2,733	3,690	1,167	3,027	4,388	1,190	2,882	3,715	7,839	11,402	9,728	8,500	11,374	14,298	16,590	6,342	7,693	2,439	1,385	1,725	418	1,910
Restricted cash
110	110	110	110	110	110	55	55	55	55	55	55	55	55	55	55	275	275	-	-	-	-	-	-	-	-	-	-	-	-	250	1,000
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	275	-	-	0	-	-	-	-	-	-	-	-	-	-
Accounts receivable, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,055	2,012	1,280	-	29	48	91	139	299	520	259	141	175	1
Prepaid expenses
1,337	862	430	813	835	509	290	440	495	250	157	228	294	171	120	209	227	193	201	239	263	193	266	325	1,017	280	559	2,347	2,521	122	39	31
Research and development tax rebate receivable
734	739	568	406	237	518	480	-	-	358	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development tax rebate receivable
-	-	-	-	-	-	-	626	395	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other accounts receivable
-	-	-	-	-	-	-	-	-	-	4	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventory, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	170	101	94	9	45	1	-	0	-	-	-	-	-	-
Other current assets
134	26	2	0	27	30	161	50	9	16	-	-	-	0	0	-	0	110	-	-	-	0	-	-	-	-	-	-	-	-	-	-
Assets of discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	636	-	-	-	-	-	-	-	-	-	-
Retainers (deposits)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	43	47	-	-	1	2
Total current assets
11,667	14,319	16,400	18,388	20,779	11,549	13,922	16,408	5,735	7,898	2,950	3,976	1,516	3,254	4,563	1,454	3,385	4,294	9,542	13,755	11,366	9,340	11,715	14,673	17,700	6,761	8,595	5,355	4,165	1,989	885	2,945
Furniture and equipment, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	129	-	443	205	150	159	67	80
Furniture and equipment, net
29	34	39	44	48	54	57	60	59	11	14	18	27	55	84	114	145	171	484	360	381	136	185	127	129	163	443	205	150	159	67	80
Intangible assets, net
60	68	76	83	91	99	55	59	70	75	561	585	610	640	1,401	1,447	1,492	1,700	1,768	1,822	1,877	1,886	4,365	4,454	4,491	4,395	4,407	4,457	4,559	4,640	4,703	40
Right-of-use asset
37	50	63	75	88	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	509	570	0	351	426	501	-	651	-	-	-	-	-	-
Other assets
17	17	17	17	17	17	88	48	114	178	108	128	148	194	227	268	76	76	52	52	176	48	-	-	4,553	36	4,443	4,494	4,595	4,676	4,739	45
Security deposit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78	61	61	-	36	36	36	36	36	5
Total Assets
11,812	14,489	16,596	18,609	21,024	11,720	14,124	16,577	5,980	8,164	3,634	4,709	2,303	4,144	6,278	3,284	5,100	6,243	12,357	16,561	13,802	11,764	16,772	19,819	22,383	12,009	13,482	10,055	8,911	6,826	5,692	3,071
Current liabilities
Line of Credit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	250	1,000
Accounts payable
356	293	501	318	463	353	550	191	168	334	380	495	386	254	197	282	429	814	1,179	580	966	513	439	790	0	248	31	184	34	68	72	64
Accrued expenses
52	77	225	53	74	177	51	286	172	90	50	44	34	16	12	75	169	463	934	1,900	1,117	254	393	226	-	295	-	-	1,901	-	1,888	442
Accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	744	-	1,069	1,289	-	1,342	-	-
Deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8	21	35	48	60	72	-	0	-	-
Payroll liabilities
466	899	769	589	891	935	706	952	356	784	627	482	330	769	635	492	724	1,159	1,156	840	1,279	959	682	508	195	580	357	196	-	207	-	-
Stock-based compensation liability
-	-	-	-	-	1,410	2,180	1,557	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lease liability
29	39	49	51	50	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock warrant liability
-	-	-	-	-	-	-	-	-	-	-	864	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Short-term lease obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	72	79	-	-	-	-	-	-	-	-	-	-	-
Product recall liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	12	96	211	402	-	-	0	-	-
Short-term lease obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	-	-	-	-	-	-
Other current liabilities
3	12	18	19	9	39	66	23	23	15	13	19	22	6	18	22	3	64	22	20	42	42	12	4	10	8	20	31	-	32	-	-
Liabilities of discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	494	-	-	-	-	-	-	-	-	-	-
Note payable - related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	80	5
Total current liabilities
907	1,322	1,564	1,032	1,491	2,915	3,555	3,011	720	1,225	1,071	1,905	774	1,047	863	874	1,326	2,501	3,292	3,413	3,486	2,263	1,539	1,563	1,082	1,401	1,942	1,774	1,936	1,650	2,290	1,512
Long term liabilities
Lease liability long term
8	11	14	24	37	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent, net of current portion
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5	10	7	2	-	-	-	0	-	-	-	-	-	-
Long-term lease obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	12	25	-	-	-	-	5	-	-	-	-	-	-
Total Liabilities
915	1,333	1,578	1,056	1,528	2,915	-	-	-	-	-	-	-	-	-	-	-	2,501	3,298	3,436	3,519	2,265	-	-	-	1,407	-	-	-	-	-	-
Commitments and contingencies (Note 12)
-	-	-	-	-	-	0	0	0	-	0	0	0	0	-	0	0	0	0	0	0	0	-	-	-	0	-	-	-	-	-	-
Stockholders' equity
Preferred stock - $0.001 par value; 10,000,000 shares authorized; 671 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively
0	0	0	0	0	0	0	0	0	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Additional paid-in capital-Series B convertible preferred stock
-	-	-	-	-	-	-	5,801	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Additional paid-in capital - Series B convertible preferred stock
670	670	670	675	701	2,378	3,516	-	-	-	-	744	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock - $0.18 par value; 175,000,000 shares authorized, and 9,130,984 shares issued and outstanding, as of March 31, 2020 and December 31, 2019, respectively
1,643	1,643	1,643	1,643	1,641	1,052	994	877	477	477	210	150	56	56	56	39	38	32	30	29	27	24	24	24	24	18	17	15	14	12	12	11
Additional paid-in capital
105,600	104,912	104,156	103,400	98,056	82,204	80,811	-	-	71,887	-	-	60,478	-	60,137	57,355	56,996	54,643	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Additional paid-in capital
-	-	-	-	-	-	-	78,330	72,082	-	65,785	63,126	-	60,344	-	-	-	-	55,001	54,751	48,766	44,648	44,569	44,347	44,204	31,099	29,281	22,522	18,634	14,894	11,415	6,200
Accumulated deficit
-97,018	-94,071	-91,453	-88,167	-80,904	-76,831	-74,753	-71,443	-67,300	-65,426	-63,433	-61,248	-59,007	-57,303	-54,780	-54,984	-53,262	-50,934	-45,973	-41,655	-38,509	-35,174	-29,361	-26,116	-22,928	-20,516	-17,758	-14,257	-11,673	-9,731	-8,026	-4,652
Total Stockholders' Equity
10,896	13,156	15,018	17,552	19,496	8,805	10,569	13,566	5,259	6,938	2,562	2,803	1,528	3,097	5,414	2,410	3,773	3,741	9,059	13,124	10,283	9,498	15,232	18,255	21,301	10,601	11,539	8,280	6,975	5,175	3,401	1,559
Total Liabilities and Stockholders' Equity
11,812	14,489	16,596	18,609	21,024	11,720	14,124	16,577	5,980	8,164	3,634	4,709	2,303	4,144	6,278	3,284	5,100	6,243	12,357	16,561	13,802	11,764	16,772	19,819	22,383	12,009	13,482	10,055	8,911	6,826	5,692	3,071